ODTX (Odyssey Therapeutics) Change In Receivables: $0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ODTX Odyssey Therapeutics Inc ODTX
13 GF Score
Price $26.49
! 2 Warning Signs
View Full Analysis

What is Odyssey Therapeutics Change In Receivables?

Odyssey Therapeutics ODTX +6.93% 13 Change In Receivables is $0.00 Mil as of Jun. 2026. GuruFocus rates ODTX with a GF Score™ of 13/100. The stock has 2 warning signs investors should review.

Odyssey Therapeutics's change in receivables for the quarter that ended in Jun. 2026 was $0.00 Mil. It means Odyssey Therapeutics's Accounts Receivable stayed the same from Mar. 2026 to Jun. 2026 .

Odyssey Therapeutics's change in receivables for the fiscal year that ended in Dec. 2025 was $0.00 Mil. It means Odyssey Therapeutics's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

Odyssey Therapeutics's Accounts Receivable for the quarter that ended in Jun. 2026 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Odyssey Therapeutics's liquidation value for the three months ended in Jun. 2026 was $247.95 Mil.

Odyssey Therapeutics  (NAS:ODTX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Odyssey Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of liquidation value, Odyssey Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Odyssey Therapeutics's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=310.575-62.629+0.75 * 0+0.5 * 0
=247.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Odyssey Therapeutics Change In Receivables Related Terms

Odyssey Therapeutics Change In Receivables Historical Data

* Premium members only.

The historical data trend for Odyssey Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Odyssey Therapeutics Change In Receivables Chart

Odyssey Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Change In Receivables
0.00 0.00 0.00 0.00

Odyssey Therapeutics Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Jun25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
ODTX
13GF Score
Odyssey Therapeutics Inc ODTX
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Odyssey Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $0.00 Mil mean?
Odyssey Therapeutics (ODTX) has a Change In Receivables of $0.00 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Odyssey Therapeutics and its competitors.
Is Odyssey Therapeutics' Change In Receivables too high?
Odyssey Therapeutics' current Change In Receivables is $0.00 Mil. Overall, Odyssey Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Odyssey Therapeutics' Change In Receivables compare to SANA and GERN?
Odyssey Therapeutics' Change In Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Odyssey Therapeutics and its competitors. Odyssey Therapeutics's current Change In Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Odyssey Therapeutics stock overvalued right now?
Odyssey Therapeutics (ODTX) has a current Change In Receivables of $0.00 Mil. The current Change In Receivables is $0.00 Mil. Odyssey Therapeutics' overall GF Score™ is 13/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Odyssey Therapeutics (ODTX), the current Change In Receivables is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Odyssey Therapeutics Business Description

Address 51 Sleeper Street, Boston, MA, USA, 02210
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
13GF Score

Get the complete analysis for ODTX

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.49
Price